Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis

References

• MeuneCTouséETrinquartLAllanoreYTrends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studiesRheumatology (Oxford)2009481309131319696061
   PubMed Web of Science ®Google Scholar
• MacGregorAJSniederHRigbyASCharacterizing the quantitative genetic contribution to rheumatoid arthritis using data from twinsArthritis Rheum200043303710643697
   PubMed Web of Science ®Google Scholar
• SilmanAJMacGregorAJThomsonWTwin concordance rates for rheumatoid arthritis: results from a nationwide studyBr J Rheumatol1993329039078402000
   PubMedGoogle Scholar
• BoissierMCSemeranoLChallalSSaidenberg-KermanacKNFalgaroneGRheumatoid arthritis: from autoimmunity to synovitis and joint destructionJ Autoimmun20123922222822704962
   PubMed Web of Science ®Google Scholar
• ArvikarSLCollierDSFisherMCClinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritisArthritis Res Ther201315R10924017968
   PubMed Web of Science ®Google Scholar
• Rantapaa-DahlqvistSde JongBABerglinEAntibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis Rheum2003482741274914558078
   PubMed Web of Science ®Google Scholar
• SmolenJLandewéRBMeasePEfficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnn Rheum Dis20096879780419015207
   PubMed Web of Science ®Google Scholar
• KeystoneECGenoveseMCKlareskogLGolimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnn Rheum Dis20096878979619066176
   PubMed Web of Science ®Google Scholar
• BuchMHBinghamSJBryerDEmeryPLong-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial respondersRheumatology (Oxford)2007461153115617478470
   PubMed Web of Science ®Google Scholar
• PaiSPaiLBirkenfeldtRCorrelation of serum IgA rheumatoid factor levels with disease severity in rheumatoid arthritisScand J Rheumatol1998272522569751464
   PubMed Web of Science ®Google Scholar
• van der Helm-van MilAHVerpoortKNBreedveldFCToesREHuizingaTWAntibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritisArthritis Res Ther20057R949R95816207336
   PubMed Web of Science ®Google Scholar
• EmeryPFleischmannRFilipowicz-SosnowskaAThe efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trialArthritis Rheum2006541390140016649186
   PubMed Web of Science ®Google Scholar
• TakPPRigbyWFRubbert-RothAInhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trialAnn Rheum Dis201170394620937671
   PubMed Web of Science ®Google Scholar
• MeasePJCohenSGaylisNBEfficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trialJ Rheumatol20103791792720194448
   PubMed Web of Science ®Google Scholar
• DassSRawstronACVitalEMHenshawKMcGonagleDEmeryPHighly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritisArthritis Rheum2008582993299918821683
   PubMed Web of Science ®Google Scholar
• VitalEMRawstronACDassSReduced-dose rituximab in rheumatoid arthritisArthritis Rheum20116360360821360489
   PubMed Web of Science ®Google Scholar
• TengYKLevarhtEWToesREHuizingaTWvan LaarJMResidual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulationAnn Rheum Dis2009681011101618647852
   PubMed Web of Science ®Google Scholar
• SellamJRouanetSHendel-ChavezHBlood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritisArthritis Rheum2011633692370122127692
   PubMed Web of Science ®Google Scholar
• PisetskyDSGrammerACNingTCLipskyPEAre autoantibodies the targets of B-cell-directed therapy?Nat Rev Rheumatol2011755155621808289
   PubMed Web of Science ®Google Scholar
• LeandroMJCambridgeGEhrensteinMREdwardsJCWReconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis Rheum20065461362016447239
   PubMed Web of Science ®Google Scholar
• RollPDörnerTTonyHPAnti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatmentArthritis Rheum2008581566157518512772
   PubMed Web of Science ®Google Scholar
• O’NeillSKShlomchikMJGlantTTCaoYDoodesPDFinneganAAntigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritisJ Immunol20051743781378815749919
   PubMed Web of Science ®Google Scholar
• ChanOTHannumLGHabermanAMMadaioMPShlomchikMJA novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupusJ Exp Med19991891639164810330443
   PubMed Web of Science ®Google Scholar
• Tanaka-WatanabeYMatsumotoIIwanamiKB cells play a crucial role as antigen-presenting cells and collaborate with inflammatory cytokines in glucose-6-phosphate isomerase-induced arthritisClin Exp Immunol200915528529419032549
   PubMed Web of Science ®Google Scholar
• TakemuraSKlimiukPABrownAGoronzyJJWeyandCMT cell activation in rheumatoid synovium is B cell dependentJ Immunol20011674710471811591802
   PubMed Web of Science ®Google Scholar
• van de VeerdonkFLLauwerysBMarijnissenRJThe anti-CD20 antibody rituximab reduces the Th17 cell responseArthritis Rheum2011631507151621400475
   PubMed Web of Science ®Google Scholar
• MouraRAGraçaLFonsecaJETo B or not to B: the conducter of rheumatoid arthritis orchestraClin Rev Allergy Immunol20124328129122717935
   PubMed Web of Science ®Google Scholar
• MatsumotoMLoSFCarruthersCJAffinity maturation without germinal centres in lymphotoxin-alpha-deficient miceNature20063824624668684487
   PubMed Web of Science ®Google Scholar
• RennertPDJamesDMackayFBrowningJLHochmanPSLymph node genesis is induced by signaling through the lymphotoxin beta receptorImmunity1998971799697837
   PubMed Web of Science ®Google Scholar
• BuchMHSmolenJSBetteridgeNUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritisAnn Rheum Dis20117090992021378402
   PubMed Web of Science ®Google Scholar
• Martinez-GamboaLBrezinschekHPBurmesterGRDörnerTImmunopathologic role of B lymphocytes in rheumatoid arthritis: rational of B cell-directed therapyAutoimmun Rev2006543744216920569
   PubMed Web of Science ®Google Scholar
• NakouMKatsikasGSidiropoulosPRituximab therapy reduces antivated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical responseArthritis Res Ther200911R13119715572
   PubMed Web of Science ®Google Scholar
• KavanaughARosengrenSLeeSJAssessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker resultsAnn Rheum Dis20086740240817644541
   PubMed Web of Science ®Google Scholar
• GheitaTAGheitaHAKenawySARituximab restored the muscle power and rescued from a refractory fatal respiratory failure in a patient with elderly-onset polymyositisJoint Bone Spine20127910110221840235
   PubMed Web of Science ®Google Scholar
• Rubbert-RothATakPPZerbiniCEfficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR)Rheumatology (Oxford)2010491683169320463186
   PubMed Web of Science ®Google Scholar
• CohenSBEmeryPGreenwaldMWRituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksArthritis Rheum2006542793280616947627
   PubMed Web of Science ®Google Scholar
• KeystoneECCohenSBEmeryPMultiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX studyJ Rheumatol2012392238224623027887
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJManeiroJRRuizJComparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR StudyAnn Rheum Dis2012711861186422736086
   PubMed Web of Science ®Google Scholar
• SolimanMMHyrichKLLuntMWatsonKDSymmonsDPAsh-croftDMRituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics RegisterArthritis Care Res20126411081115
   PubMed Web of Science ®Google Scholar
• EmeryPDeodharARigbyWFEfficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)Ann Rheum Dis2010691629163520488885
   PubMed Web of Science ®Google Scholar
• ChatzidionysiouKLieENasonovEEffectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaborationAnn Rheum Dis20127137437721972242
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatid drugsAnn Rheum Dis20106996497520444750
   PubMed Web of Science ®Google Scholar
• SinghJAFurstDEBharatA2012 Update of the 2008 American College of Rheumatology recommendations for the use of diseas-modifying antirheumatic drugs and biologic agents in the treatment of theumatoid arthritisArthritis Care Res (Hoboken)20126462563922473917
   PubMed Web of Science ®Google Scholar
• CantaertTKollnJTimmerTB lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesisJ Immunol200818178579418566445
   PubMed Web of Science ®Google Scholar
• NevesMAlvesJDFactors implicated in the generation and persistence of long-lived plasma cell-mediated autoimmunityAutoimmun Rev20111037538221224017
   PubMed Web of Science ®Google Scholar
• HumbyFBombardieriMManzoAEctopic lymphoid structures support ongoing production of class-switch autoantibodies in rheumatoid synoviumPLoS Med200965975
   Web of Science ®Google Scholar
• KlimiukPAGoronzyJJBjörnssonJBeckenbaughRDWeyandCMTissue cytokine patterns distinguishes variants of rheumatoid synovitisAm J Pathol1997151131113199358757
   PubMed Web of Science ®Google Scholar
• FonsecaJECanhãoHResendeCHistology of the synovium tissue: value of semi-quantitative analysis for the prediction of joint erosions in rheumatoid arthritisClin Exp Rheumatol20001855956411072594
   PubMed Web of Science ®Google Scholar
• MeiHESchmidtSDörnerTRational of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunityArthritis Res Ther201214Suppl 5S123281743
   PubMed Web of Science ®Google Scholar
• YazawaNHamaguchiYPoeJCTedderTFImmunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune diseaseProc Natl Acad Sci U S A2005102151781518316217038
   PubMed Web of Science ®Google Scholar
• HamaguchiYUchidaJCainDWThe peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in miceJ Immunol20051744389439915778404
   PubMed Web of Science ®Google Scholar
• TedderTFCD19: a promising B cell target for rheumatoid arthritisNat Rev Rheumatol2009557257719798033
   PubMed Web of Science ®Google Scholar
• StoneMJSausvilleEAFayJWA Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphomaBlood199688118811978695836
   PubMed Web of Science ®Google Scholar
• YounesAKimSRomagueraJPhase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphomaJ Clin Oncol2012302776278222753910
   PubMed Web of Science ®Google Scholar
• JinXDingCBelimumab – an anti-BLyS human monoclonal antibody for rheumatoid arthritisExpert Opin Biol Ther20131331532223268610
   PubMed Web of Science ®Google Scholar
• GenoveseMCKinnmanNde La BourdonnayeGPena RossiCTakPPAtacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase II, randomized, placebo-controlled, dose-finding trialArthritis Rheum2011631793180321452293
   PubMed Web of Science ®Google Scholar
• StohlWMerrillJTMcKayJDEfficacy and safety of belimumab in patients with rheumatoid arthritis: a Phase II, randomized, double-blind, placebo-controlled, dose-ranging studyJ Rheumatol20134057958923547209
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFKinnmanNVincentEWaxSBathonJAtacicept in patients with rheumatoid arthritis and an inadequate response to methotrexateArthritis Rheum2011631782179221452294
   PubMed Web of Science ®Google Scholar
• DillonSRHarderBLewisKBB-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulinArthritis Res Ther201012R4820302641
   PubMed Web of Science ®Google Scholar
• FiresteinGSEtiology and pathogenesis of rheumatoid arthritisFiresteinGSBuddRCHarrisEDJMcInnesIBRuddySSergentJSKelley’s Textbook of Rheumatology8th edPhiladelphia, PASaunders2009
   Google Scholar
• KoendersMILubbertsEvan de LooFAJInterleukin-17 acts independently of TNF-alpha under arthritic conditionsJ Immunol20061766262626916670337
   PubMed Web of Science ®Google Scholar
• DienzORinconMThe effects of IL-6 on CD4 T cell responsesClin Immunol2009130273318845487
   PubMed Web of Science ®Google Scholar
• KishimotoTIL-6: from its discovery to clinical applicationsInt Immunol20102234735220410258
   PubMed Web of Science ®Google Scholar
• SzodorayPNakkenBBarathSAltered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disordersHum Immunol8202013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• MatsukiFSaegusaJMiyamotoYMisakiKKumagaiSMorinobuACD45RA-Foxp3high activated/effector regulatory T cells in the CCR7+CD45RA-CD27+CD28+ central memory subset are the decreased in peripheral blood from patients with rheumatoid arthritisBiochem Biophys Res Commun201343877878323747721
   PubMed Web of Science ®Google Scholar
• EsenstenJHWofsyDBluestoneJARegulatory T cells as therapeutic targets in rheumatoid arthritisNat Rev Rheumatol2009556056519798031
   PubMed Web of Science ®Google Scholar
• CeerazSHallCChoyESpencerJCorrigallVMDefective CD8+CD28-regulatory T cell suppressor function in rheumatoid arthritis is restored by TNF inihibitor therapyClin Exp Immunol2013174182623786396
   PubMed Web of Science ®Google Scholar
• SzalayBVásárhelyiBCsehAThe impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up studyClin Rheumatol8112013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• SolomonGET-cell agents in the treatment of rheumatoid arthritisBull NYU Hosp Jt Dis20127019119423259627
   PubMedGoogle Scholar
• BuchMHBoyleDLRosengrenSMode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot studyAnn Rheum Dis2009681220122718772191
   PubMed Web of Science ®Google Scholar
• WeismanMHDurezPHalleguaDReduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritisJ Rheumatol2006332162216617014006
   PubMed Web of Science ®Google Scholar
• von KempisJDudlerJHaslerPUse of abatacept in rheumatoid arthritisSwiss Med Wkly2012142w1358122581564
   PubMed Web of Science ®Google Scholar
• GottenbergJERavaudPCantagrelAPositivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registryAnn Rheum Dis2012711815181922615458
   PubMed Web of Science ®Google Scholar
• KremerJMGenantHKMorelandLWEffects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trialAnn Intern Med200614486587616785475
   PubMed Web of Science ®Google Scholar
• SchiffMKeisermanMCoddingCEfficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, doubleblind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnn Rheum Dis2008671096110318055472
   PubMed Web of Science ®Google Scholar
• GenoveseMCBeckerJCSchiffMAbatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionN Engl J Med20053531114112316162882
   PubMed Web of Science ®Google Scholar
• SchiffMKeisermanMCoddingCClinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST StudyAnn Rheum Dis2011702003200721914628
   PubMed Web of Science ®Google Scholar
• SchiffMPritchardCHuffstutterJEThe 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialAnn Rheum Dis2009681708171419074911
   PubMed Web of Science ®Google Scholar
• WesthovensRRoblesMXimenesACClinical efficacy and safety of abatacept in methotrexate naive patients with early rheumatoid arthritis and poor prognostic factorsAnn Rheum Dis2009681870187719124524
   PubMed Web of Science ®Google Scholar
• SchiffMSubcutaneous abatacept for the treatment of rheumatoid arthritisRheumatology (Oxford)20135298699723463804
   PubMed Web of Science ®Google Scholar
• NashPNayiagerSGenoveseMCImmunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label studyArthritis Care Res (Hoboken)20136571872823097311
   PubMed Web of Science ®Google Scholar
• PieperJHerrathJRaghavanSMuhammadKvan VollenhovenRMalmströmVCTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patientsBMC Immunol2013143423915385
   PubMed Web of Science ®Google Scholar
• WeinblattMSchiffMGoldmanASelective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trialAnn Rheum Dis20076622823416935912
   PubMed Web of Science ®Google Scholar
• BrennenFMMcLnnesIVEvidence that cytokines play a role in rheumatoid arthritisJ Clin Invest20081183537354518982160
   PubMed Web of Science ®Google Scholar
• ChoyEUnderstanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritisRheumatology (Oxford)201251Suppl 5v3v1122718924
   PubMed Web of Science ®Google Scholar
• GerneroPThompsonEWoodworthTSmolenJSRapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexateArthritis Rheum201062334320039425
   PubMed Web of Science ®Google Scholar
• DayerJMChoyETherapeutic targets in rheumatoid arthritis: the interleukin-6 receptorRheumatology (Oxford)201049152419854855
   PubMed Web of Science ®Google Scholar
• NunomuraWHatakeyamaM[Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipo-protein B in LDL at phosphorylcholine-binding site of CRP]Hokkaido Igaku Zasshi199065474480 Japanese2227796
   PubMedGoogle Scholar
• MattssonNMagnussenCGRönnemaaTMetabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns studyArterioscler Thromb Vasc Biol2010301861186620539018
   PubMed Web of Science ®Google Scholar
• ArtlAMarscheGLestavelSSattlerWMalleERole of serum amyloid A during metabolism of acute-phase HDL by macrophagesArterioscler Thromb Vasc Biol20002076377210712402
   PubMed Web of Science ®Google Scholar
• BankaCLYuanTde BeerMCKindyMCurtissLKde BeerFCSerum amyloid A (SAA): influence on HDL-mediated cellular cholesterol effluxJ Lipid Res199536105810657658153
   PubMed Web of Science ®Google Scholar
• LeeHYKimSDBaekSHSerum amyloid A stimulates macrophage foam cell formation via lectin-like oxidized low-density lipo-protein receptor 1 upregulationBiochem Biophys Res Commun2013433182323454129
   PubMed Web of Science ®Google Scholar
• PatelAMMorelandLWInterleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapyDrug Des Dev Ther20104263278
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trialLancet200837198799718358926
   PubMed Web of Science ®Google Scholar
• FleischmannRMHallandAMBrzoskoMTocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year resultsJ Rheumatol201340211312623322466
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheu-matic drug therapy studyArthritis Rheum200858102968298018821691
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum200858102968298018821691
   PubMed Web of Science ®Google Scholar
• DougadosMKisselKSheeranTAdding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Ann Rheum Dis201372435022562983
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab mono-therapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnn Rheum Dis2010691889619297346
   PubMed Web of Science ®Google Scholar
• SalliotCvan der HeijdeDLong-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature researchAnn Rheum Dis2009681100110419060002
   PubMed Web of Science ®Google Scholar
• HanselBBruckertE[Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: effect of the disease and of drug therapy]Ann Endocrinol (Paris)201071257263 French20416859
   PubMed Web of Science ®Google Scholar
• OliveiraSPatient with a 9-year history of rheumatoid arthritis and hepatitis B co-infection who responds favorably to tocilizumab mono-therapy after progression or intolerance to several disease-modifying anti-rheumatic drugsAdv Ther201229 Special Issue1213
   Google Scholar
• Rose-JohnSIL-6 Trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6Int J Biol Sci201281237124723136552
   PubMed Web of Science ®Google Scholar
• NowellMAWilliamsASCartySATherapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritisJ Immunol200918261362219109195
   PubMed Web of Science ®Google Scholar
• BarkhausenTTschernigTRosenstielPSelective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis modelCrit Care Med2011391407141321336117
   PubMed Web of Science ®Google Scholar
• MurrayPJThe JAK-STAT signaling pathway: input and output integrationJ Immunol20071782623262917312100
   PubMed Web of Science ®Google Scholar
• TanakaYYamaokaKJAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinicalMod Rheumatol20132341542423212593
   PubMed Web of Science ®Google Scholar
• van der HeijdeDTanakaYFleischmannRTofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyArthritis Rheum201365355957023348607
   PubMed Web of Science ®Google Scholar
• FleischmannRKremerJCushJPlacebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritisN Eng J Med20123676495507
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFFleischmannRCohenSTofacitinib or adalimumab versus placebo in rheumatoid arthritisN Eng J Med20123676508519
   PubMed Web of Science ®Google Scholar
• KremerJLiZGHallSTofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialAnn Intern Med2013159425326124026258
   PubMed Web of Science ®Google Scholar
• BresnihanBAlvaro-GraciaJMCobbyMTreatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonistArthritis Rheum199841219622049870876
   PubMed Web of Science ®Google Scholar
• CohenSHurdECushJTreatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheum20024661462411920396
   PubMed Web of Science ®Google Scholar
• CohenSBMorelandLWCushJJA multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexateAnn Rheum Dis2004631062106815082469
   PubMed Web of Science ®Google Scholar
• ThalerKChandiramaniDVHansenRAGeraldGEfficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review ProjectBiologics2009348549820054439
   PubMedGoogle Scholar
• ReichertJMWhich are the antibodies to watch in 2013?MAbs201351423254906
   PubMed Web of Science ®Google Scholar
• TakPPMeasePJGenoveseMCSafety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trialArthritis Rheum20126436037022389919
   PubMed Web of Science ®Google Scholar
• RigbyWTonyHPOelkeKSafety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate – results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group Phase III trialArthritis Rheum20126435035921905001
   PubMed Web of Science ®Google Scholar
• AletahaDAlastiFSmolenJSRituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patientsAnn Rheum Dis20137271222915619
   PubMed Web of Science ®Google Scholar
• SmolenJSMartinez AvilaJCAletahaDTocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: dissociation of the link between inflammation and destructionAnn Rheum Dis20127168769322121130
   PubMed Web of Science ®Google Scholar